Novartis Brings On First Tigit Drug In Massive Billion-Dollar Biobucks Deal With Beigene
After Watching Gilead Sciences And Roche Dive Deeper Into Tigit Immunotherapies, Novartis Is Heading Straight For The Senior Class. The Swiss Pharma Is Getting In On The Game Via A Blockbuster Deal With Beigene, Which Could Ultimately Net $1 Billion For A Late-Stage Asset.Novartis Will Pay $300 Million Upfront And Could Shell Out Up To $700 Million Down The Line In Milestones For The Tigit Inhibitor Ociperlimab If An Option Is Exercised Before 2023, According To A Monday Statement. This Is Novartis
Optimize Your trial insights with Clival Database.
Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.
With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.
To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.
Elevate your trial success rate with the cutting-edge insights from Clival database.
Check it out today and make more informed sourcing decisions! Learn More!
